Skip to main content
OpenTrials
Completed

NCT Number: NCT01321931

Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products

Multiple-dose nicotine pharmacokinetics with three oral nicotine replacement products. A study in healthy smokers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

McNeil AB Clinical Pharmacology R&D

Lund, SE-222 20, Sweden

About this study

Fifty (50) healthy male or female subjects between the ages of 19 and 50 years, inclusive, smoking at least 20 cigarettes daily during at least one year preceding inclusion. Multiple doses of all study treatments are given either every 60 minutes or every 90 minutes, respectively. All products will be administered in accordance with labeling, on five separate treatment visits. The subjects will abstain from smoking from 8 pm in the evening before and until the end of each visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects, smoking at least 20 cigarettes daily during at least one year preceding inclusion.
  • BMI between 17.5 and 30.0 kg/m2 and a total body weight of at least 55.0 kg.
  • Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
  • A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
  • Willing and able to comply with all scheduled visits and study procedures

Exclusion criteria

  • Pregnancy, lactation or intended pregnancy.
  • Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
  • Any medical condition or history that might, per protocol or in the opinion of the investigator, compromise subject safety or trial results.

Treatment and study plan

nicotine

Drug

6 mg experimental Nicotine Replacement Therapy (NRT)

Other names: Not yet marketed

Primary outcomes

  1. Maximum Observed Plasma Concentration

    Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)

    Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma within the last dosing interval, measured in nanograms/milliliter (ng/mL)

  2. Average Concentration

    Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)

    Average Nicotine Plasma Concentration (Cav) within the last dosing interval

  3. Area Under the Curve

    Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)

    Area under the nicotine plasma concentration-vs.-time curve during the last dosing interval (AUCt)

Secondary outcomes

  1. Time of Maximum Concentration

    Time frame: During 12 hours post-dose

    The time at which maximum concentration is reached (Tmax)

  2. Minimum Observed Concentration

    Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)

    Minimum Observed Plasma Concentration (Cmin), which is the minimum concentration (amount of drug) measurable in blood plasma within the last dosing interval, measured in nanograms/milliliter (ng/mL)

  3. Peak-Trough Fluctuation

    Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)

    Percent of Peak-Trough Fluctuation in one dosing interval at steady state (PTF)

  4. Swing

    Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)

    Swing in one dosing interval at steady state, calculated as (Cmax-Cmin)/ Cmin

  5. Nicotine Released

    Time frame: 30 minutes

    The amount of nicotine released from the product during product administration

Sponsors and collaborators

Lead sponsor

McNeil AB

Industry

Registry information

Official study title

Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Mar 24, 2011
Registry last updated
Jul 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.